Watson Pharmaceuticals Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Watson's performance against key rivals in the prescription pharmaceutical sector

*Assess how large scale M&A activity undertaken by a number of Watson's peers has intensified competitive threat to future sales growth

*Analyze how Watson will seek to bolster its performance in the generic pharmaceutical market via its branded offering and distribution business


Report Highlights

[Studien Infos ausblenden]

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Watson: PharmaVitae forecasts at a glance 8
Strategic insight 9
Watson left trailing by M&A activity across competitor base 9
Watson announces Arrow Acquisition 11
SWOT analysis 12
Strengths 12
Weaknesses 13
Opportunities 14
Threats 14
Table of Contents 16
Table of figures 18
Chapter 3 Quarterly news update 19
Product developments 19
Deals and alliances 19
Product deals 19
Technology deals 20
M&A activity 21
Company announcements 21
Chapter 4 Company introduction 22
Key findings 22
Background 23
Key corporate developments 23
M&A history 23
Andrx acquisition 25
M&A strategy 25
Deals and alliances 26
Current corporate structure 26
Chapter 5 Company sales 27
Key findings 27
Prescription pharmaceutical sales and growth rate analysis, 2002-14 28
Product analysis 30
Product analysis, 2002-08 31
Product analysis, 2008-14 34
Therapy area analysis 37
Geographic analysis 39
Molecule type analysis 40
Chapter 6 Company financials 41
Key findings 41
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 42
Operating costs and profit analysis 43
Operating costs and profit analysis, 2002-08 44
Operating cost ratio and profit margin analysis, 2002-08 45
Operating cost ratio and profit margin analysis, 2008-14 46
Operating costs and profit analysis, 2008-14 47
Chapter 7 Key products and competitors 48
Overview 48
Genitourinary 49
Oral contraceptives (generic) 49
Overview 49
Sales forecast 50
Rapaflo 51
Overview 51
Sales forecast 52
Cardiovascular 53
diltiazem 53
Overview 53
Sales forecast 54
Oncology 55
Trelstar 55
Overview 55
Sales forecast 56
Central nervous system 57
fentanyl 57
Overview 57
Sales forecast 58
hydrocodone 59
Overview 59
Sales forecast 60
oxycodone/Apap 61
Overview 61
Sales forecast 62
bupropion 63
Overview 63
Sales forecast 64
Chapter 8 Appendix 65
Abbreviations 65
Exchange rates 66
About Datamonitor 67
About Datamonitor Healthcare 67
Datamonitor consulting 67
Disclaimer 69
List of Tables
Table 1: Watson - PharmaVitae forecasts at a glance 8
Table 2: Watson key product developments, Q1-Q2 2009 19
Table 3: Watson product deals and alliances, Q1-Q2 2009 19
Table 4: Watson technology deals and alliances, Q1-Q2 2009 20
Table 5: Watson M&A activity, Q1-Q2 2009 21
Table 6: Watson company announcements, Q1-Q2 2009 21
Table 7: Watson product portfolio overview ($m), 2002-08 31
Table 8: Watson product portfolio overview ($m), 2008-14 34
Table 9: Watson prescription pharmaceutical sales by therapy area ($m), 2008-14 38
Table 10: Total Watson sales by business unit ($m), 2002-08 42
Table 11: Watson operating revenue/cost analysis ($m), 2002-08 44
Table 12: Watson operating cost ratio analysis (% of total revenues), 2002-08 45
Table 13: Watson operating cost ratio analysis (% of total revenues), 2008-14 46
Table 14: Watson operating revenue/cost analysis ($m), 2008-14 47
Table 15: Watson key products overview 48
Table 16: Oral contraceptives (generic): overview 49
Table 17: Oral contraceptives (generic): sales forecast ($m), 2008-14 50
Table 18: Rapaflo: overview 51
Table 19: Rapaflo: sales forecast ($m), 2008-14 52
Table 20: diltiazem: overview 53
Table 21: diltiazem: sales forecast ($m), 2008-14 54
Table 22: Trelstar: overview 55
Table 23: Trelstar: sales forecast ($m), 2008-14 56
Table 24: fentanyl: overview 57
Table 25: fentanyl: sales forecast ($m), 2008-14 58
Table 26: hydrocodone: overview 59
Table 27: Hydrocodone: sales forecast ($m), 2008-14 60
Table 28: oxycodone/Apap: overview 61
Table 29: oxycodone/Apap: sales forecast ($m), 2008-14 62
Table 30: bupropion: overview 63
Table 31: bupropion: sales forecast ($m), 2008-14 64
Table 32: Exchange rates, 2009 66
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Watson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Watson's financial performance ($m), 2002-14 7
Figure 4: Watson SWOT analysis 10
Figure 5: Watson SWOT analysis 12
Figure 6: Motives driving forward Watson's acquisitions, 2002-06 23
Figure 7: M&A/divestment history 25
Figure 8: Current corporate structure 26
Figure 9: Watson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 28
Figure 10: Watson Key product sales ($m), 2002-14 30
Figure 11: Watson key sales growth drivers ($m), 2002-08 32
Figure 12: Watson key sales growth drivers and resistors ($m), 2008-14 36
Figure 13: Watson prescription pharmaceutical sales by therapy area ($m), 2002-14 37
Figure 14: Watson prescription pharmaceutical sales by geographic region ($m), 2002-14 39
Figure 15: Watson prescription pharmaceutical sales by molecule type ($m), 2002-14 40
Figure 16: Watson operating revenue/cost analysis ($m), 2002-14 43

[Inhaltsverzeichnis ausblenden]